- Details
- Ruchika Talwar interviews Kristian Stensland about his publication in Urology Practice on the size and scope of urologic oncology clinical trials. Dr. Stensland discusses their analysis of trials registered on clinicaltrials.gov since 2007, revealing that over 100 patients enroll daily in urologic oncology trials, totaling about 28,000 participants annually. Despite this significant number, enroll...
|
- Details
- Rahul Aggarwal presents findings on targeting DLL3 in neuroendocrine prostate cancer. He explains that DLL3 is highly expressed in high-risk neuroendocrine prostate cancer, particularly in the treatment-emergent form seen after androgen deprivation therapy. This Phase 1b study expanded on prior research in small cell lung cancer and included 40 patients with broad inclusion criteria for DLL3 posit...
|
- Details
- Ashish Kamat hosts a discussion with Matt Galsky and Neal Shore on the latest advancements in bladder cancer treatment, focusing on immunotherapy for advanced bladder cancer and the associated survival benefits. He emphasizes the importance of recognizing and managing immune-related toxicities. Dr. Shore discusses the application of immunotherapy in earlier stages of disease, mentioning pembrolizu...
|
- Details
- Pedro Barata engages in a discussion with Martin Voss about volrustomig, a novel PD-1/CTLA-4 bispecific antibody for advanced clear cell RCC. Dr. Voss provides an overview of volrustomig, highlighting its unique ability to inhibit PD-1 and selectively bind CTLA-4 on cells co-expressing both receptors, aiming for targeted action in the tumor microenvironment. He reviews the dose-finding study's pro...
|
- Details
- Alicia Morgans hosts Guru Sonpavde and Bradley McGregor to discuss the DAD trial, which uniquely combines enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), for advanced urothelial carcinoma. Dr. Sonpavde highlights the distinct mechanisms and non-overlapping toxicities of these drugs. Funded by Gilead, the trial adopts a Phase I BOIN design, starting with lower dos...
|
- Details
- Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with lut...
|
- Details
- Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...
|
- Details
- Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors, u...
|
- Details
- Medical Oncologists Alicia Morgans and Mark Markowski discuss challenges in treating advanced prostate cancer, related to the evolving resistance requiring novel mechanisms of action to give us new options for treatment. A new drug, masofaniten (formerly EPI-7386), is being studied in a phase II trial for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to enroll 120 patient...
|
- Details
- Oliver Sartor discusses the REASSURE study with Alicia Morgans. The study investigates the long-term side effects of radium, the first approved alpha emitter, on prostate cancer patients. With over 1,400 patients involved, the study monitors side effects such as fractures, bone marrow failure, and secondary malignancies over the course of years. Interestingly, the study found fewer side effects th...
|
